Hostname: page-component-cd9895bd7-hc48f Total loading time: 0 Render date: 2024-12-18T16:19:07.594Z Has data issue: false hasContentIssue false
  • English
  • Français

Anticuerpos antinucleares en esquizofrenia y trastorno depresivo mayor: un enigma que se mantiene

Published online by Cambridge University Press:  12 May 2020

K. Schott ,
A. Uhl ,
A. Batra ,
M. Bartels ,
B. Eusterschulte  and
G. Buchkremer
K. Schott
Affiliation:
Universitätsklinik für Psychiatrie und Psychotherapie, Tubinga
A. Uhl
Affiliation:
Universitätsklinik für Psychiatrie und Psychotherapie, Tubinga
A. Batra
Affiliation:
Universitätsklinik für Psychiatrie und Psychotherapie, Tubinga
M. Bartels
Affiliation:
Universitätsklinik für Psychiatrie und Psychotherapie, Tubinga
B. Eusterschulte
Affiliation:
Fachklinik Rottrenmünster, Rottweil, Alemania
G. Buchkremer
Affiliation:
Universitätsklinik für Psychiatrie und Psychotherapie, Tubinga
Get access

Resumen

Se cribó el suero de pacientes con trastorno depresivo mayor y esquizofrenia paranoide para anticuerpos antinucleares (antígenos: DNA-ds, ENA, histona H3) y complejos inmunes circulantes (CIC-Cq1) con ELISA. Los controles eran donantes de sangre sanos. Sólo algunas muestras de suero de los pacientes fueron positivas para los anticuerpos anti-DNA-ds y anti-ENA. No hubo resultados significativos. En esquizofrenia paranoide, 20,5% de las muestras fueron positivas para los anticuerpos contra la histona H3. En el caso de los CIC-Cq1, 7% de los pacientes con trastorno depresivo mayor y 11% de los pacientes con esquizofrenia paranoide fueron positivos. Hubo muestras positivas en 39% de los controles. Este estudio discrepa de trabajos anteriores que pudieron demostrar una serie de anticuerpos antinucleares en trastornos mentales. En el caso de los anticuerpos antihistona, los presentes resultados podrían indicar un proceso autoinmune en un subgrupo de pacientes esquizofrénicos.

Keywords

anticuerpos antinucleareshistonastrastorno depresivo mayoresquizofrenia
Type
Comunicación breve
Information
European Psychiatry (Ed. Española) , Volume 4 , Issue 2 , March 1997 , pp. 114 - 118
Copyright
Copyright © European Psychiatric Association 1997

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Bibliografia

Alarcon-Segovia, DFischbein, ECetina, JARaya, RJBarrera, EAntigenic specificity of chlorpromazine-induced antinuclear antibodies. Clin Exp Immunol 1973; 15: 543–8.Google ScholarPubMed
Berglund, SGottfries, CGGotfries, IStormby, KChlorpromazine- induced antinuclear factors. Acta Med Scand 1970; 187: 67–74.CrossRefGoogle ScholarPubMed
Brauchitsch, HAntinuclear factor in psychiatric disorders. Am J Psychiatry 1972; 128: 1552–4.CrossRefGoogle Scholar
Canoso, RTOliveira, RMNixon, RANeuroleptic associated autoantibodies. A prevalence study. Biol Psychiatry 1990; 27: 863–70.CrossRefGoogle ScholarPubMed
Chengappa, KNRCarpenter, ABYang, ZWBrar, JSRabin, BSGanguli, RElevated IgG antihistone antibodies in a subgroup of medicated schizophrenic patients. Schizophrenia Res 1992; 7: 49–54.CrossRefGoogle Scholar
Debert, RVan Hooren, JBiesbrouck, MAmery, WAAntinuclear factor - positive mental depression: a single disease entity? Biol Psychiatry 1976; 11: 69–74.Google Scholar
Ganguli, RRabin, BSKelly, RHLyte, MRagu, UClinical and laboratory evidence of autoinmunity in acute schizophrenia. Ann NY Acad Sci 1987; 496: 676–85.CrossRefGoogle Scholar
Gompertz, NRIsenberg, DATumer, BMCorrelation between clinical features of systemic lupus erythematosus and levels of antihistone antibodies of the IgG, IgA, and IgM isotypes. Ann Rheum Dis 1990; 49: 524–7.CrossRefGoogle ScholarPubMed
Gottfries, CGGottfries, IAntinuclear factors in relation to age, sex, mental disease and treatment with phenothiazines. Acta Psychiatr Scand 1974; 255 (Suppl): 193–201.CrossRefGoogle ScholarPubMed
Johnston, ECWhaley, KAntinuclear antibodies in psychiatric ilness: their relationship to diagnosis and drug treatment. Br Med J 1975; 2: 724–5.CrossRefGoogle Scholar
Legros, SMendlewicz, JWybran, JImmunoglobulins, autoantibodies and other serum protein fractions in psychiatric disorders. Eur Arch Psychiatr Neurol Sci 1985; 235: 9–11.CrossRefGoogle ScholarPubMed
Maes, MBosmans, ESuy, EVandervorst, CDejonckheere, CRaus, JAntiphospholipid, antinuclear, Epstein-Bar and cytomegalovirus antibodies, and soluble interleukin- 2 receptors in depressive patients. J Affective Dis 1991; 21: 133–40.CrossRefGoogle Scholar
Sirota, PFirer, MAShild, KTanay, AElizure, AMeytes, DSlor, HAutoantibodies to DNA in multicase families with schizophrenia. Biol Psychiatry 1993; 33: 450–5.CrossRefGoogle ScholarPubMed
Spitzer, RLEndicott, JRobins, EResearch diagnostic criteria. Arch Gen Psychiatry 1987; 35: 773–82.CrossRefGoogle Scholar
Tan, EMAntinuclear antibodies: diagnostic markers for autoinmune diseases and probes for cell biology. Adv Immunol 1989; 44: 93–151.CrossRefGoogle Scholar
Villemain, FMagnin, MFeuillet-Fieux, MNZarifian, ELoo, HBach, JFAntihistone antibodies in schizophrenia and affective disorders. Psychiatry Res 1988; 24: 53–60.CrossRefGoogle Scholar
Yannitsi, SGManoussakis, MNMauridis, AK et al. Factors related to the presence of autoantibodies in patients with chronic mental disorders. Biol Psychiatry 1990; 27: 747–56.CrossRefGoogle ScholarPubMed